{
  "source": "PA-Notification-Firdapse.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1275-7\nProgram Prior Authorization/Notification\nMedication Firdapse® (amifampridine)\nP&T Approval Date 2/2019, 1/2020, 1/2021, 1/2022, 11/2022, 11/2023. 11/2024\nEffective Date 2/1/2025\n1. Background:\nFirdapse (amifampridine) is a potassium channel blocker indicated for the treatment of Lambert-\nEaton myasthenic syndrome (LEMS) in adults and pediatric patients 6 years of age and older.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Firdapse will be approved based on both of the following criteria:\na. Diagnosis of Lambert-Eaton myasthenic syndrome (LEMS)\n-AND-\nb. Patient is not receiving Firdapse in combination with similar potassium channel\nblockers [e.g., Ampyra (dalfampridine)]\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Firdapse will be approved based on both the following criteria:\na. Documentation of positive clinical response to Firdapse therapy\n-AND-\nb. Patient is not receiving Firdapse in combination with similar potassium channel\nblockers [e.g., Ampyra (dalfampridine)]\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n© 2024 UnitedHealthcare Services, Inc.\n1\n3. Additional Clinical Programs:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits and Medical Necessity may be in place.\n4. References:\n1. Firdapse [package insert]. Catalyst Pharmaceuticals, Inc. Coral Gables, FL. May 2024.\nProgram Prior Authorization/Notification - Firdapse (amifampridine)\nChange Control\n2/2019 New program\n1/2020 Annual review with no chang",
    "rt]. Catalyst Pharmaceuticals, Inc. Coral Gables, FL. May 2024.\nProgram Prior Authorization/Notification - Firdapse (amifampridine)\nChange Control\n2/2019 New program\n1/2020 Annual review with no changes.\n1/2021 Annual review with no changes.\n1/2022 Annual review with no change to clinical criteria. Updated reference.\n11/2022 Updated background to reflect new pediatric indication for patients 6\nyears of age and older. Added state mandate footnote.\n11/2023 Added “Diagnosis of” to initial criteria with no change to clinical intent.\n11/2024 Annual review with no changes to coverage criteria. Updated reference.\n© 2024 UnitedHealthcare Services, Inc.\n2"
  ]
}